On 12 June 2024, Boston-based Zumutor Biologics announced that it has commenced its open-label, first-in-human, multicentre, Ph 1 trial of ZM008 in patients with advanced solid tumours. The trial (NCT06451497) is evaluating ZM008 alone and in combination with pembrolizumab. ZM008 is a fully human IgG1 monoclonal antibody against LLT1 and disrupts LLT1’s interaction with CD16 receptor on natural killer cells.
The FDA granted Zumutor’s Investigational New Drug (IND) application for ZM008 on 11 August 2023.